Vascular responses to drug-eluting and bare metal stents in diabetic/hypercholesterolemic and nonatherosclerotic porcine coronary arteries

Circulation: Cardiovascular Interventions

Volumn 4, Issue 5, 2011, Pages 438-446

  Llano, Raul ^a   Winsor Hines, Dawn ^b   Patel, Dhavalkumar B ^a   Seifert, Paul S ^b   Hamamdzic, Damir ^a   Wilson, Gregory J ^c   Wang, Hong ^b   Keane, Martin G ^a   Huibregtse, Barbara A ^b   Wilensky, Robert L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOSTON SCIENTIFIC CORPORATION   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Animal models of human disease; Coronary stent; Diabetes mellitus; Paclitaxel eluting stent; Restenosis; Vascular response

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; GLUCOSE; HEPARIN; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; BLOOD VESSEL REACTIVITY; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ELUTING STENT; DRUG IMPLANTATION; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; LEUKOCYTE; MALE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; SWINE; T LYMPHOCYTE; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CELL MOVEMENT; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIABETES COMPLICATIONS; DISEASE PROGRESSION; DRUG-ELUTING STENTS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; MODELS, ANIMAL; NEOINTIMA; PACLITAXEL; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SWINE; T-LYMPHOCYTES;

EID: 82955240695     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.959957     Document Type: Article

References (30)

1. Suzuki T, Kopia G, Hayashi S, Llano G, Wilensky RL, Klugherz BD, Papandreou G, Narayan P, Adelman S, Leon MB, Young AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation and instent restenosis in a porcine coronary model. Circulation. 2001;104:1188-1193. (Pubitemid 32830406)
2. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreau G, Narayanan P, Sasseen B, Adelman S, Falotico R, Wilensky RL. Twenty-eight day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002;13:183-188. (Pubitemid 34747967)
3. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, Tanguay J-F, Holper EM, Abbott JD, Lee JS, Smith C, Anderson WD, Kelsey SF, Kip KE. A comparison of bare metal and drug-eluting stents for off-label indications: findings from the NHLBI Dynamic Registry. N Engl J Med. 2008;358:342-352. (Pubitemid 351159233)
4. Abbott JD, Voss MR, Nakamura M, Cohen HA, Selzer F, Kip KE, Vlachos HA, Wilensky RL, Williams DO. Comparison of drug eluting to bare metal stents in routine clinical practice: Findings from the NHLBI Dynamic Registry. J Am Coll Cardiol. 2007;50:2029-2036.
5. Gerrity RG, Natarajan R, Nadler JL, Kimsey T. Diabetes-induced accelerated atherosclerosis in swine. Diabetes. 2001;50:1654-1665. (Pubitemid 33639607)
6. Mohler ER III, Sarov-Blat L, Shi Y, Hamamdzic D, Zalewski A, MacPhee C, Llano, Pelchovitz DR, Mainigi SK, Osman H, Hallman T, Steplewski K, Gertz Z, Lu MM, Wilensky RL. Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol. 2008;28:850-855. (Pubitemid 351544098)
7. Wilensky RL, Shi Y, Mohler ER III, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerosis plaque development. Nat Med. 2008;14:1059-1066.
8. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC. Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model. Cardiovasc Res. 2007;76:361-372. (Pubitemid 350214456)
9. Seifert PS, Huibregtse BA, Polovick J, Poff B. Early vascular response to overlapped paclitaxel-eluting stents in swine coronary arteries. Cardiovasc Revasc Med. 2007;8:251-258. (Pubitemid 350161453)
10. Wilson GJ, Nakazawa G, Schwartz RS Huibregtse B, Poff B, Herbst TJ, Baim D, Virmani R. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009;120:141-149.
11. Drachman DE, Edelman ER, Seifert P Groothuis AR, Bornstein DA, Kamath KR, Palasis M, Yang D, Nott SH, Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol. 2000;36:2325-2332.
12. Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G, Fineberg N, Hathaway DR. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation. 1995; 92:2995-3005.
13. Shi Y, Zhang P, Zhang L, Osman H, Mohler ER III, Macphee C, Zalewski A, Anthony Postle, Wilensky RL. Role of lipoproteinassociated phospholipase A2 in leukocyte activation and inflammatory response. Atherosclerosis. 2007;191:54-62. (Pubitemid 46227429)
14. Hamamdzic D, Fenning RS, Patel D, Mohler ER III, Orlova KA, Wright AC, Llano R, Keane MG, Shannon RP, Birnbaum MJ, Wilensky RL. The Akt pathway is hypo-activated by the synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease. Am J Physiol Heart Circ Physiol. 2010;299:699-706.
15. Moreno PR, Murca AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180-2184.
16. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271. (Pubitemid 38880019)
17. Pennathur S, Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid Redox Signal. 2007;9:955-969. (Pubitemid 46919596)
18. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Compl. 2001;15:44-51.
19. Gewirtz H, Steiner M, Sasken H, Most AS. Measurement by electrical impedance aggregometry of porcine platelets response to selected physiological agonists. Proc Soc Exp Biol Med. 1985;179:324-330. (Pubitemid 15042879)
20. Galvez A, Badimon L, Badimon JJ, Fuster V. Electrical aggregometry in whole blood from human, pig and rabbit. Thromb Haemost. 1986;56: 128-132. (Pubitemid 17178784)
21. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051-1058. (Pubitemid 46328299)
22. Tellez A, Krueger CG, Seifert P, Winsor-Hines D, Piedrahita C, Cheng Y, Milewski K, Aboodi MS, Yi G, McGregor JC, Crenshaw T, Reed JD, Huibregste B, Kaluza GL, Granada JF. Coronary bare metal stent implantation in homozygous LDL receptor deficient swine induces a neointimal formation pattern similar to humans. Atherosclerosis. 2010;213:518-524.
23. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arteroscler Thromb Vasc Biol. 2007;27:1500-1510. (Pubitemid 46986103)
24. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
25. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberb J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231. (Pubitemid 38067635)
26. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico RL. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617-624. (Pubitemid 39078675)
27. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697. (Pubitemid 26320276)
28. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-181. (Pubitemid 43005183)
29. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705. (Pubitemid 38222887)
30. Suzuki N, Angiolillo DJ, Monteiro C, Shuja S, Futamatsu H, Kawaguchi R, Box LC, Guzman L, Zenni MM, Gilmore PS, Bass TA, Costa MA. Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents. Int J Cardiol. 2008;130:444-448.